QSAR Modelling for Drug Discovery: Predicting the Activity of LRRK2 Inhibitors for Parkinson's Disease Using Cheminformatics Approaches

Parkinson’s disease is one of the most common neurodegenerative disorders in elder people and the leucine-rich repeat kinase 2 (LRRK2) is a promising target for its pharmacological treatment. In this paper, QSAR models for identification of potential inhibitors of LRRK2 protein are designed by using an in house chemical library and several machine learning methods. The applied methodology works in two steps: first, several alternative subsets of molecular descriptors relevant for characterizing LRRK2 inhibitors are identified by a feature selection software tool; secondly, QSAR models are inferred by using these subsets and three different methods for supervised learning. The performance of all these QSAR models are assessed by traditional metrics and the best models are analyzed in statistical and physicochemical terms.

[1]  Andrew B West,et al.  G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons , 2016, The Journal of Neuroscience.

[2]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[3]  Andrew B West,et al.  Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Aalizadeh,et al.  3D-QSAR and molecular docking study of LRRK2 kinase inhibitors by CoMFA and CoMSIA methods , 2016, SAR and QSAR in environmental research.

[5]  Mati Karelson,et al.  Topological Fingerprints as an Aid in Finding Structural Patterns for LRRK2 Inhibition , 2014, Molecular informatics.

[6]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[7]  Víctor Sebastián-Pérez,et al.  Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. , 2017, European journal of medicinal chemistry.

[8]  Anthony A Estrada,et al.  Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors. , 2015, Journal of medicinal chemistry.

[9]  Paul J Gilligan,et al.  Inhibitors of leucine-rich repeat kinase 2 (LRRK2): progress and promise for the treatment of Parkinson's disease. , 2015, Current topics in medicinal chemistry.

[10]  Gustavo Henrique Goulart Trossini,et al.  Use of machine learning approaches for novel drug discovery , 2016, Expert opinion on drug discovery.

[11]  Scott Boyer,et al.  Choosing Feature Selection and Learning Algorithms in QSAR , 2014, J. Chem. Inf. Model..

[12]  Mark R Cookson,et al.  LRRK2 Pathways Leading to Neurodegeneration , 2015, Current Neurology and Neuroscience Reports.